REPR is the maker of the Freedom60 that delivers the drug Hizentra.
The makers of Hizentra had their earnings release on February and mentioned particularly good results. Their family of immunoglobin drugs grew sales 22%, with CSL noting this was in part due to the increased demand for Hizentra specifically as well as a competitor recently withdrawing itself from the market. As well, CSL announced their additional production capacity is now complete, to support more growth in Hizentra sales.
This should further help explode REPR sales, net income, and EPS.
